WO2004070034A3 - Oligonukleotide gerichtet gegen ein survivin-gen und die verwendung dieser - Google Patents

Oligonukleotide gerichtet gegen ein survivin-gen und die verwendung dieser Download PDF

Info

Publication number
WO2004070034A3
WO2004070034A3 PCT/DE2004/000263 DE2004000263W WO2004070034A3 WO 2004070034 A3 WO2004070034 A3 WO 2004070034A3 DE 2004000263 W DE2004000263 W DE 2004000263W WO 2004070034 A3 WO2004070034 A3 WO 2004070034A3
Authority
WO
WIPO (PCT)
Prior art keywords
directed against
survivin gene
oligonucleotides directed
oligonucleotides
cell
Prior art date
Application number
PCT/DE2004/000263
Other languages
English (en)
French (fr)
Other versions
WO2004070034A2 (de
Inventor
Axel Meye
Susanne Fuessel
Manfred P Wirth
Uta Schmidt
Bernd Kueppers
Helge Taubert
Matthias Kappler
Matthias Bache
Frank Bartel
Peter Wuerl
Original Assignee
Univ Dresden Tech
Univ Halle Wittenberg
Axel Meye
Susanne Fuessel
Manfred P Wirth
Uta Schmidt
Bernd Kueppers
Helge Taubert
Matthias Kappler
Matthias Bache
Frank Bartel
Peter Wuerl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Dresden Tech, Univ Halle Wittenberg, Axel Meye, Susanne Fuessel, Manfred P Wirth, Uta Schmidt, Bernd Kueppers, Helge Taubert, Matthias Kappler, Matthias Bache, Frank Bartel, Peter Wuerl filed Critical Univ Dresden Tech
Priority to EP04709196A priority Critical patent/EP1590457A2/de
Priority to US10/545,093 priority patent/US20070032440A1/en
Publication of WO2004070034A2 publication Critical patent/WO2004070034A2/de
Publication of WO2004070034A3 publication Critical patent/WO2004070034A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Abstract

Die vorliegende Erfindung betrifft Oligonukleotide, die gegen ein Survivin-Gen und dessen Varianten gerichtet sind sowie die Verwendung dieser Oligonukleotide zur Diagnose, Prophylaxe, Verminderung, Verlaufskontrolle von mit Zellwachstum, -differenzierung und/oder -teilung im Zusammenhang stehenden Krankheiten, wie beispielsweise Tumorerkrankungen.
PCT/DE2004/000263 2003-02-07 2004-02-09 Oligonukleotide gerichtet gegen ein survivin-gen und die verwendung dieser WO2004070034A2 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP04709196A EP1590457A2 (de) 2003-02-07 2004-02-09 Oligonukleotide gerichtet gegen ein survivin-gen und die verwendung dieser
US10/545,093 US20070032440A1 (en) 2003-02-07 2004-02-09 Oligonucleotides directed against a survivin gene and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10306083A DE10306083A1 (de) 2003-02-07 2003-02-07 Erkennungsmoleküle gerichtet gegen ein Survivin-Gen und die Verwendung dieser
DE10306083.9 2003-02-07

Publications (2)

Publication Number Publication Date
WO2004070034A2 WO2004070034A2 (de) 2004-08-19
WO2004070034A3 true WO2004070034A3 (de) 2005-02-10

Family

ID=32797391

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2004/000263 WO2004070034A2 (de) 2003-02-07 2004-02-09 Oligonukleotide gerichtet gegen ein survivin-gen und die verwendung dieser

Country Status (4)

Country Link
US (1) US20070032440A1 (de)
EP (1) EP1590457A2 (de)
DE (1) DE10306083A1 (de)
WO (1) WO2004070034A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009114476A1 (en) * 2008-03-12 2009-09-17 Intradigm Corporation Compositions comprising survivin sirna and methods of use thereof
DE102011100581A1 (de) 2011-05-04 2012-11-08 Eberhard-Karls-Universität Tübingen Universitätsklinikum Behandlung von hyperproliferativen Erkrankungen des Urogenitaltraktes
CN105177000A (zh) * 2015-08-13 2015-12-23 吉林大学 一种抑制Survivin基因表达的siRNA及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001057059A1 (en) * 2000-02-02 2001-08-09 Isis Pharmaceuticals, Inc. Antisense modulation of survivin expression
US6346389B1 (en) * 1998-04-01 2002-02-12 Yale University Method for selectively modulating the interactions between survivin and tubulin

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346389B1 (en) * 1998-04-01 2002-02-12 Yale University Method for selectively modulating the interactions between survivin and tubulin
WO2001057059A1 (en) * 2000-02-02 2001-08-09 Isis Pharmaceuticals, Inc. Antisense modulation of survivin expression

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
"A ribozyme-based gene therapy approach to target the survivin pathway in human prostate cancer cells", EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, vol. 38, November 2002 (2002-11-01), pages S147, XP004403936, ISSN: 0959-8049 *
DATABASE GSN 17 July 2002 (2002-07-17), "Human API4 antisense oligonucleotide #10", XP002289624, retrieved from EBI Database accession no. ABZ21956 *
DATABASE GSN 17 July 2002 (2002-07-17), "Human API4 antisense oligonucleotide #11", XP002289625, retrieved from EBI Database accession no. ABZ21957 *
DATABASE GSN 17 July 2002 (2002-07-17), "Human API4 antisense oligonucleotide #7", XP002289623, retrieved from EBI Database accession no. ABZ21953 *
OLIE ROBERT A ET AL: "A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 60, no. 11, 1 June 2000 (2000-06-01), pages 2805 - 2809, XP002210584, ISSN: 0008-5472 *
TOBAL K ET AL: "Expression and DNAzyme targeting of the apoptosis inhibitor, survivin in myeloid leukemias", BLOOD, W.B.SAUNDERS COMPAGNY, ORLANDO, FL, US, vol. 96, no. 11 Part 1, 16 November 2000 (2000-11-16), pages 216a, XP009019357, ISSN: 0006-4971 *
TOBAL K ET AL: "SURVIVIN-TARGETING DNAZYMES EFFICIENTLY CLEAVE ITS TRANSCRIPTS AND INDUCE APOPTOSIS IN MYELOID LEUKAEMIAS", BRITISH JOURNAL OF HAEMATOLOGY, OXFORD, GB, vol. 117, no. SUPPL 1, May 2002 (2002-05-01), pages 44, XP009018746, ISSN: 0007-1048 *

Also Published As

Publication number Publication date
WO2004070034A2 (de) 2004-08-19
US20070032440A1 (en) 2007-02-08
EP1590457A2 (de) 2005-11-02
DE10306083A1 (de) 2004-09-02

Similar Documents

Publication Publication Date Title
AP2212A (en) Phosphonates, Monophosphonamidates, Bisphosphonamidates for the treatment of viral diseases.
EP1581656A4 (de) MODULATION DER EXPRESSION VON HIF1a UND HIF2a
WO2004111603A3 (en) Gene expression markers for predicting response to chemotherapy
WO2005019418A3 (en) Modulation of diacylglycerol acyltransferase 2 expression
WO2007035752A3 (en) Low acrylamide foods
WO2004074455A3 (en) Fc REGION VARIANTS
WO2006009765A3 (en) Methods for the identification and use of compounds suitable for the treatment of drug resistant cancer cells
WO2006004955A3 (en) Nucleotide sequences and polypeptides encoded thereby useful for modifying plant characteristics and phenotypes
WO2004080418A3 (en) Nucleic acid compounds for inhibiting angiogenesis and tumor growth
WO2004048534A3 (en) Modulation of cytokine-inducible kinase expression
WO2004011610A3 (en) Antisense modulation of polo-like kinase expression
WO2007084162A3 (en) Sirtuin inhibiting compounds
WO2006132739A3 (en) Novel chemical compounds
PL1948689T3 (pl) Mutanty czynników wzrostu o wysokiej aktywności
WO2007062380A3 (en) Modulation of eif4e-bp2 expression
WO2004110245A3 (en) Combination therapy for cancer treatment
WO2006056304A3 (en) Control of indoleamine 2,3 deoxygenase expression and activity
WO2005042552A3 (en) Modulation of sglt2 expression
WO2006088368A3 (en) Dna-based coatings for implants
WO2006066154A3 (en) Casein kinase 2 antisense therapy
WO2006094722A3 (en) Growth factor mutants with improved biological activity
WO2004070034A3 (de) Oligonukleotide gerichtet gegen ein survivin-gen und die verwendung dieser
WO2007064853A3 (en) Locked nucleic acid oligonucleotides
WO2006127458A3 (en) Novel chemical compounds
WO2005005382A3 (en) Compounds, compositions and methods

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2004709196

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004709196

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007032440

Country of ref document: US

Ref document number: 10545093

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10545093

Country of ref document: US